CARTESIAN Aktie

 

NEW YORK, June 20, 2025 /PRNewswire/ -- Cartesian Growth Corporation III (the "Company") announced today that, commencing on or about Tuesday, June 24, 2025, holders of the units sold in the Company's initial public offering may elect to separately trade the Class A ordinary shares and......

FREDERICK, Md., June 03, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced the granting of inducement awards to three new employees. On June 2, 2025, the Company issued to these employees options to purchase an aggregate of 26,350 shares of the Company's common stock with an exercise price of $9.98, the closing trading price of the Company's common stock on the Nasdaq Global Market on the date of grant. The options were granted pursuant to the Company's Amended and Restated 2018 Employment Inducement Incentive Award Plan and were approved by the Company's board of directors. The options vest as to 25% on June 2, 2026, and then in three equal annual installments thereafter such that the options will be fully vested on June 2, 2029. The options have a ten-year term. The options were granted under Rule 5635(c)(4) of the Nasdaq Listing Rules as an inducement mat...

FREDERICK, Md., May 30, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (“Cartesian” or the “Company”), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced that the first participant has been enrolled in its Phase 3 AURORA trial of Descartes-08 in patients with myasthenia gravis (MG)....

Initiation of Phase 3 AURORA trial of Descartes-08 in myasthenia gravis expected in 2Q25; deep and sustained benefits observed through Month 12 after a single course of therapy in Phase 2b trial...

NEW YORK--(BUSINESS WIRE)--Cartesian Growth Corporation III (the “Company”) announced today the closing of its initial public offering of 27,600,000 units, including 3,600,000 units pursuant to the exercise of the underwriters' over-allotment option. The offering was priced at $10.00 per unit generating total gross proceeds of $276,000,000. The Company's sponsor is an affiliate of Cartesian Capital Group, LLC, a global private equity firm specializing in providing growth capital to transnational businesses. The units are listed on The Nasdaq Stock Market LLC (“Nasdaq”) and trade under the symbol “CGCTU”. Each unit consists of one Class A ordinary share and one-half of one redeemable warrant, with each whole warrant entitling the holder to purchase one Class A ordinary share at a price of $11.50 per share. Once the securities comprising the units begin separate trading, the Class A ordinary shares and warrants are expected to be listed on Nasdaq under the symbols “CGCT” and “CGCTW”, r...

FREDERICK, Md., May 02, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering cell therapy for the treatment of autoimmune diseases, today announced the granting of inducement awards to five new employees. On May 1, 2025, the Company issued to these employees options to purchase an aggregate of 27,700 shares of the Company's common stock with an exercise price of $12.27, the closing trading price of the Company's common stock on the Nasdaq Global Market on the date of grant. The options were granted pursuant to the Company's Amended and Restated 2018 Employment Inducement Incentive Award Plan and were approved by the Company's board of directors. The options vest as to 25% on May 1, 2026, and then in three equal annual installments thereafter such that the options will be fully vested on May 1, 2029. The options have a ten-year term. The options were granted under Rule 5635(c)(4) of the Nasdaq Listing Rules as an i...

NEW YORK--(BUSINESS WIRE)--Cartesian Growth Corporation III (the “Company”) announced today the pricing of its initial public offering of 24,000,000 units, upsized from 20,000,000 units, at a price of $10.00 per unit. The units are expected to commence trading on May 2, 2025 on The Nasdaq Stock Market LLC (“Nasdaq”) under the symbol “CGCTU”. The Company's sponsor is an affiliate of Cartesian Capital Group, LLC, a global private equity firm specializing in providing growth capital to transnational businesses. Each unit consists of one Class A ordinary share and one-half of one redeemable warrant, with each whole warrant entitling the holder to purchase one Class A ordinary share at a price of $11.50 per share. Once the securities comprising the units begin separate trading, the Class A ordinary shares and warrants are expected to be listed on Nasdaq under the symbols “CGCT” and “CGCTW”, respectively. No fractional warrants will be issued upon separation of the units and only whole warr...

Springer, Timothy A. - Aufsichtsrat - Tag der Transaktion: 2025-04-09...

Springer, Timothy A. - Aufsichtsrat - Tag der Transaktion: 2025-04-10...

Springer, Timothy A. - Aufsichtsrat - Tag der Transaktion: 2025-04-11...

The Nordic Innovation Award was presented for the first time in Copenhagen on April 10. The Norwegian company Cartesian won the award for its groundbreaking innovation. The Norwegian company Cartesian has developed a thermal energy storage solution for large heating and cooling systems. It can be charged with heat or cold when the energy supply is good and the prices are low, and release the energy when the need and prices are high. The innovative solution of its thermal battery consists of a unique combination of advanced phase change materials, heat exchange technology, and precise...

After a single course of therapy, Descartes-08-treated participants were observed to sustain deep responses through long-term follow-up, with an average 4.8-point reduction in MG-ADL at Month 12...

FREDERICK, Md., April 02, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering cell therapies for the treatment of autoimmune diseases, today announced the granting of inducement awards to four new employees. On April 1, 2025, the Company issued to these employees options to purchase an aggregate of 31,000 shares of the Company's common stock with an exercise price of $12.49, the closing trading price of the Company's common stock on the Nasdaq Global Market on the date of grant. The options were granted pursuant to the Company's Amended and Restated 2018 Employment Inducement Incentive Award Plan and were approved by the Company's board of directors. The options vest as to 25% on April 1, 2026, and then in three equal annual installments thereafter such that the options will be fully vested on April 1, 2029. The options have a ten-year term. The options were granted under Rule 5635(c)(4) of the Nasdaq Listing Rul...

FREDERICK, Md., April 01, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapies for autoimmune diseases, today announced that its management expects to participate in a fireside chat at the 24th Annual Needham Virtual Healthcare Conference on Tuesday, April 8, 2025, at 2:15 p.m. ET....

Springer, Timothy A. - Aufsichtsrat - Tag der Transaktion: 2025-03-18...

Springer, Timothy A. - Aufsichtsrat - Tag der Transaktion: 2025-03-20...

Springer, Timothy A. - Aufsichtsrat - Tag der Transaktion: 2025-03-19...

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

Phase 3 AURORA trial of Descartes-08 in myasthenia gravis on track to commence in 1H25; Deep and durable responses maintained over 12 months in Descartes-08-treated participants in Phase 2b trial...

Jeftovic: We're Already Living In A Post-Singularity World Authored by Mark Jeftvic via BombThrower.com, In mathematics, a singularity is where the equations go “non-linear”.  Inputs go in, but the outputs are beyond understanding.  In physics, it's where the laws of three-dimensional Cartesian reality break down. Ray Kurzweil hijacked the term and applied it to AI and exponential computing power: Moore's Law would bring us all past the point where technology accelerates beyond human comprehension. For Techno-Utopians, among them – the transhumanists - the Singularity will bring about a kind of eschatological event, a computerized “End Times” like a Rapture moment wherein technology acquires more brainpower than all of humanity combined, and deftly solves all our problems (unless the techno-doomers are right, and it annihilates us instead). In Frazzledrip Overdrive, a recent piece that looked at ever-accelerating Future Shock, and the iterations of mass formation psychosis ...